会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • VARIANT HCMV PP65, IE1, AND IE2 POLYNUCLEOTIDES AND USES THEREOF
    • 各种HCMV PP65,IE1和IE2多核苷酸及其用途
    • US20110136896A1
    • 2011-06-09
    • US13056899
    • 2009-07-28
    • Tong-Ming FuDanilo R. CasimiroDaniel C. FreedAimin Tang
    • Tong-Ming FuDanilo R. CasimiroDaniel C. FreedAimin Tang
    • A61K31/7088C07H21/04C07K14/005C12N15/63C12P21/06
    • C07K14/005C12N2710/16122
    • The present invention relates to compositions and methods to elicit or enhance cell-mediated immunity against HCMV infection by providing polynucleotides encoding variant HCMV pp65, IE1, and IE2 proteins, and fusion proteins thereof. The present invention also provides recombinant vectors including, but not limited to, adenovirus and plasmid vectors comprising said polynucleotides and host cells comprising said recombinant vectors. Also provided herein are purified forms of the variant HCMV pp65, IE1, and IE2 proteins described herein, and fusion proteins. The variant HCMV proteins, and fusion proteins thereof, are useful as vaccines for the protection from and/or treatment of HCMV infection. Said vaccines are useful as a monotherapy or a part of a therapeutic regime, said regime comprising administration of a second vaccine such as a polynucleotide, cell-based, protein or peptide-based vaccine.
    • 本发明涉及通过提供编码变体HCMV pp65,IE1和IE2蛋白的多核苷酸及其融合蛋白来引发或增强细胞介导的HCMV感染免疫的组合物和方法。 本发明还提供重组载体,包括但不限于腺病毒和包含所述多核苷酸的质粒载体和包含所述重组载体的宿主细胞。 本文还提供了本文所述的变体HCMV pp65,IE1和IE2蛋白的纯化形式,以及融合蛋白。 变体HCMV蛋白及其融合蛋白可用作用于保护和/或治疗HCMV感染的疫苗。 所述疫苗可用作单一疗法或治疗方案的一部分,所述方案包括施用第二种疫苗,例如多核苷酸,基于细胞的,蛋白质或基于肽的疫苗。